Online citations, reference lists, and bibliographies.
← Back to Search

Drug Resistance In Cancer And Role Of Nanomedicine-Based Natural Products

Deeptashree Nandi, Aakriti Singal, Alo Nag
Published 2019 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Cancer is an age-old malady that has claimed millions of lives across the globe and the death toll is ever increasing. Despite intensive research for over a decade, contemporary anticancer treatment regimens still suffer from certain shortcomings, with drug resistance posing as a major hurdle. In this aspect, natural anticancer products have attracted attention as suitable chemopreventive agents over other synthetic compounds. However, the potential application of such natural compounds has been restricted due to their low bioavailability, poor efficacy amongst other limitations. An exciting advancement in the field of medicine has been the advent of nanoparticles that have reformed the usage of natural products as innovative anticancer therapeutics. This chapter elaborates the role of nanoparticle based natural products as potent and efficacious therapeutic agents for treatment and management of cancer.
This paper references
10.2174/156652412803833508
Honokiol: a novel natural agent for cancer prevention and therapy.
S. Arora (2012)
10.1166/JBN.2014.1997
Anti-cancer activity of bromelain nanoparticles by oral administration.
P. Bhatnagar (2014)
10.1038/srep20051
Curcumin Nanoformulation for Cervical Cancer Treatment
M. Zaman (2016)
10.2147/IJN.S27864
Bypassing multidrug resistance in human breast cancer cells with lipid/polymer particle assemblies
B. Li (2012)
10.1038/nrc.2016.108
Cancer nanomedicine: progress, challenges and opportunities
J. Shi (2017)
10.1016/j.leukres.2015.10.010
Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia.
Joshua F. Zeidner (2015)
10.1093/jnci/91.1.66
Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group.
C. Gridelli (1999)
10.1002/ijc.24336
Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice
N. Narayanan (2009)
10.1016/J.BIONUT.2012.10.009
Anticancer activity of resveratrol-loaded gelatin nanoparticles on NCI-H460 non-small cell lung cancer cells
S. Karthikeyan (2013)
10.1091/mbc.E14-04-0916
How Taxol/paclitaxel kills cancer cells
Beth A. A. Weaver (2014)
10.4103/0975-7406.130965
Dendrimers in drug delivery and targeting: Drug-dendrimer interactions and toxicity issues
Kanika Madaan (2014)
10.1016/S0378-5173(00)00562-7
Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel.
A. Miglietta (2000)
10.2174/0929867325666180111095913
Stimuli Responsive Nanoparticles for Controlled Anti-cancer Drug Release.
Q. Tang (2018)
10.1016/j.biomaterials.2012.08.007
Co-delivery of paclitaxel and survivin shRNA by pluronic P85-PEI/TPGS complex nanoparticles to overcome drug resistance in lung cancer.
Jianan Shen (2012)
10.1016/j.nano.2012.05.013
The big picture on nanomedicine: the state of investigational and approved nanomedicine products.
M. Etheridge (2013)
10.1158/1078-0432.CCR-05-1634
Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel.
N. Desai (2006)
10.1016/j.nano.2012.03.003
Increased brain uptake of docetaxel and ketoconazole loaded folate-grafted solid lipid nanoparticles.
Vinay Kumar Venishetty (2013)
BIODEGRADABLE PEG NANOPARTICLES FOR COLORECTAL CANCER USING IRINOTECAN AS ANTICANCER AGENT
N. Narayanan (2014)
10.1002/smll.200900621
Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells.
A. M. Chen (2009)
10.1248/CPB.59.1471
Discovery of artemisinin-glycolipid hybrids as anti-oral cancer agents.
Jérémy Ricci (2011)
10.1126/scitranslmed.3003651
Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile
Jeffrey Hrkach (2012)
10.1200/JCO.2004.12.043
Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
P. Sabbatini (2004)
10.1007/978-3-319-41129-3_2
Nanoparticles Types, Classification, Characterization, Fabrication Methods and Drug Delivery Applications
Saurabh Bhatia (2016)
10.2217/nnm.10.35
Nanomedicinal strategies to treat multidrug-resistant tumors: current progress.
X. Dong (2010)
10.1002/jps.24388
Inhibition against growth of glioblastoma multiforme in vitro using etoposide-loaded solid lipid nanoparticles with p-aminophenyl-α-D-manno-pyranoside and folic acid.
Y. Kuo (2015)
10.1016/j.addr.2009.05.005
Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin.
M. Davis (2009)
10.1038/nrd2614
Nanoparticle therapeutics: an emerging treatment modality for cancer
M. Davis (2008)
10.1093/CARCIN/BGI040
Epigallocatechin-3-gallate induces mitochondrial membrane depolarization and caspase-dependent apoptosis in pancreatic cancer cells.
S. Qanungo (2005)
10.1038/sj.bjc.6601922
Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT)
D. Bissett (2004)
10.7314/APJCP.2013.14.4.2591
Clinical comparison between paclitaxel liposome (Lipusu®) and paclitaxel for treatment of patients with metastatic gastric cancer.
Xu Xu (2013)
10.1021/ja801969b
Magnetic nanoparticle-peptide conjugates for in vitro and in vivo targeting and extraction of cancer cells.
K. E. Scarberry (2008)
10.1007/s13277-013-0963-0
Anti-cancer activity of DHA on gastric cancer—an in vitro and in vivo study
H. Sun (2013)
10.1200/JCO.2010.28.15_SUPPL.TPS160
Dose-escalation phase I study of NKTR-105, a novel pegylated form of docetaxel.
Ester Calvo (2010)
10.18632/ONCOTARGET.543
A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy
Dipankar Pramanik (2012)
10.1016/j.ejpb.2012.12.009
Injectable nanomaterials for drug delivery: carriers, targeting moieties, and therapeutics.
David M. Webster (2013)
10.1038/nrc3599
Cancer drug resistance: an evolving paradigm
C. Holohan (2013)
10.1039/c2cs15327k
Design of polymeric nanoparticles for biomedical delivery applications.
Mahmoud Elsabahy (2012)
10.1021/mp300505w
Nanoparticle delivered vascular disrupting agents (VDAs): use of TNF-alpha conjugated gold nanoparticles for multimodal cancer therapy.
Mithun M. Shenoi (2013)
10.1166/JNN.2016.11124
Synergistic Nanomedicine: Passive, Active, and Ultrasound-Triggered Drug Delivery in Cancer Treatment.
Mohamed A Elkhodiry (2016)
10.1016/j.saa.2016.11.049
A comprehensive approach to ascertain the binding mode of curcumin with DNA.
Ps Haris (2017)
10.1093/ANNONC/MDY047.032
Artemisia absinthium extract loaded polymeric nanoparticles as the therapeutic remedy for breast cancer
M Mughees (2018)
10.1039/C6QM00289G
Clinical application of polymeric micelles for the treatment of cancer
A. Varela-Moreira (2017)
10.1016/j.ijbiomac.2017.03.137
Artemisinin loaded chitosan magnetic nanoparticles for the efficient targeting to the breast cancer.
Subramanian Natesan (2017)
10.2147/IJN.S57929
Evaluation of silica nanoparticle toxicity after topical exposure for 90 days
H. Ryu (2014)
10.1038/srep22390
Combination Therapy using Co-encapsulated Resveratrol and Paclitaxel in Liposomes for Drug Resistance Reversal in Breast Cancer Cells in vivo
Jie Meng (2016)
10.1002/pbc.27003
CNS progression during vinblastine or targeted therapies for high‐risk relapsed ALK‐positive anaplastic large cell lymphoma: A case series
Stephanie Ruf (2018)
10.1038/nrc723
Natural products in cancer chemotherapy: past, present and future
J. Mann (2002)
10.1016/j.ejmech.2008.04.021
Targeting cancer cells with biotin-dendrimer conjugates.
W. Yang (2009)
10.2147/IJN.S79489
PLGA-encapsulated tea polyphenols enhance the chemotherapeutic efficacy of cisplatin against human cancer cells and mice bearing Ehrlich ascites carcinoma
M. Singh (2015)
10.21873/ANTICANRES.12046
Anticancer Activity of Artemisinin and its Derivatives.
S. Slezáková (2017)
10.1007/s12094-012-0883-2
Efficiency and mechanism of intracellular paclitaxel delivery by novel nanopolymer-based tumor-targeted delivery system, NanoxelTM
Alka Madaan (2012)
10.1146/ANNUREV.MED.53.082901.103929
Mechanisms of cancer drug resistance.
M. Gottesman (2002)
10.1016/j.ijpharm.2013.05.015
Enhanced antitumor efficacy by methotrexate conjugated Pluronic mixed micelles against KBv multidrug resistant cancer.
Yanzuo Chen (2013)
10.1016/j.addr.2007.08.044
Protein nanoparticles as drug carriers in clinical medicine.
M. Hawkins (2008)
10.1016/j.ijrobp.2012.02.030
Polymeric nanoparticles containing taxanes enhance chemoradiotherapeutic efficacy in non-small cell lung cancer.
J. Jung (2012)
10.2174/1567201811666140206103609
New chitosan nanospheres for the delivery of 5-fluorouracil: preparation, characterization and in vitro studies.
R. Cavalli (2014)
10.1158/1078-0432.CCR-06-2821
Phase I Trial of Poly-l-Glutamate Camptothecin (CT-2106) Administered Weekly in Patients with Advanced Solid Malignancies
J. Homsi (2007)
10.1016/J.NANO.2012.05.013
THE BIG PICTURE ON SMALL MEDICINE: THE STATE OF NANOMEDICINE PRODUCTS APPROVED FOR USE OR IN CLINICAL TRIALS
M. Etheridge (2013)
10.3109/10717544.2015.1041580
Targeted delivery of doxorubicin and vincristine to lymph cancer: evaluation of novel nanostructured lipid carriers in vitro and in vivo
Xiaoyuan Dong (2016)
10.3390/cancers6031769
Drug Resistance in Cancer: An Overview
Genevieve Housman (2014)
10.1016/J.CTRV.2006.07.001
Irinotecan in the treatment of colorectal cancer.
C. Fuchs (2006)
10.1016/j.addr.2009.01.007
XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer.
A. Yurkovetskiy (2009)
10.13040/IJPSR.0975-8232.6(10).4103-12
Medicinal Plants: Their Use in Anticancer Treatment.
M. Greenwell (2015)
10.1016/j.nano.2011.06.005
Gold-doxorubicin nanoconjugates for overcoming multidrug resistance.
Yanjuan Gu (2012)
10.3390/nu4111679
Epigallocatechin Gallate (EGCG) Is the Most Effective Cancer Chemopreventive Polyphenol in Green Tea
Guang-Jian Du (2012)
10.1016/j.colsurfb.2009.03.010
Enhanced growth inhibition effect of resveratrol incorporated into biodegradable nanoparticles against glioma cells is mediated by the induction of intracellular reactive oxygen species levels.
Junfei Shao (2009)
Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy.
A. Mukerjee (2009)
10.1016/j.addr.2013.11.009
Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.
N. Bertrand (2014)
10.3109/03602532.2014.883406
Toxicity and efficacy of carbon nanotubes and graphene: the utility of carbon-based nanoparticles in nanomedicine
Y. Zhang (2014)
10.1021/nn200007z
Doxorubicin-tethered responsive gold nanoparticles facilitate intracellular drug delivery for overcoming multidrug resistance in cancer cells.
F. Wang (2011)
10.1016/j.biopha.2016.12.034
Curcumin inhibits growth potential by G1 cell cycle arrest and induces apoptosis in p53-mutated COLO 320DM human colon adenocarcinoma cells.
Jade Dhananjay Dasiram (2017)
10.1016/j.nano.2014.04.003
Pharmacodynamic and pharmacogenomic study of the nanoparticle conjugate of camptothecin CRLX101 for the treatment of cancer.
S. Gaur (2014)
10.1166/JBN.2016.2207
Curcumin-ER Prolonged Subcutaneous Delivery for the Treatment of Non-Small Cell Lung Cancer.
A. Ranjan (2016)
10.1109/TNB.2005.850478
Carbon nanotubes for biomedical applications
N. Sinha (2005)
10.1530/ERC-13-0171
Resveratrol and cancer: focus on in vivo evidence
Lindsay G. Carter (2014)
10.1080/13543776.2017.1276566
Recent progress on curcumin-based therapeutics: a patent review (2012-2016). Part I: Curcumin
R. Di Martino (2017)
10.1016/j.nano.2015.08.006
Nanomedicine applied to translational oncology: A future perspective on cancer treatment.
L. Bregoli (2016)
10.1126/SCIENCE.1060928
Carbon Nanotubes--the Route Toward Applications
R. Baughman (2002)
10.1016/J.ARABJC.2017.05.011
Nanoparticles: Properties, applications and toxicities
I. Khan (2017)
10.1021/mp400342f
Resveratrol-loaded nanoparticles based on poly(epsilon-caprolactone) and poly(D,L-lactic-co-glycolic acid)-poly(ethylene glycol) blend for prostate cancer treatment.
V. Sanna (2013)
10.15226/2374-6866/1/2/00109
Nanomedicines for Cancer Therapy: An Update of FDA Approved and Those under Various Stages of Development
G. Pillai (2014)
10.1021/nn900451a
Layer-by-Layer-Coated Gelatin Nanoparticles as a Vehicle for Delivery of Natural Polyphenols.
T. Shutava (2009)
Differential interactions of Pgp inhibitor thaliblastine with adriamycin, etoposide, taxol and anthrapyrazole CI941 in sensitive and multidrug-resistant human MCF-7 breast cancer cells.
G. Chen (1996)
10.2147/DDDT.S140797
Irinotecan and 5-fluorouracil-co-loaded, hyaluronic acid-modified layer-by-layer nanoparticles for targeted gastric carcinoma therapy
Zhuanglei Gao (2017)
10.1016/J.EJPB.2007.08.001
Nanoparticles for drug delivery: the need for precision in reporting particle size parameters.
M. Gaumet (2008)
10.1007/s00280-008-0746-2
A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma
L. C. Scott (2008)
10.1023/A:1021210910821
Mechanisms of Cancer Chemoprevention by Soy Isoflavone Genistein
F. Sarkar (2004)
10.1159/000227107
Carboplatin/etoposide/vincristine therapy in small cell lung cancer.
U. Gatzemeier (1992)
10.7314/APJCP.2015.16.5.1993
Irinotecan as a second-line chemotherapy for small cell lung cancer: a systemic analysis.
Ming-qian Zhang (2015)
10.1016/j.ijrobp.2017.03.032
Multicenter Phase 2 Study of Peri-Irradiation Chemotherapy Plus Intensity Modulated Radiation Therapy With Concurrent Weekly Docetaxel for Inoperable or Medically Unresectable Nonmetastatic Gastric Cancer.
Y. Liu (2017)
10.1016/j.clinthera.2013.10.009
Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) formulation and paclitaxel in polyethoxylated castor oil: a randomized, two-period crossover study in patients with advanced cancer.
M. Slingerland (2013)
10.1371/journal.pone.0032920
Folate Decorated Dual Drug Loaded Nanoparticle: Role of Curcumin in Enhancing Therapeutic Potential of Nutlin-3a by Reversing Multidrug Resistance
Manasi Das (2012)
Long-term topotecan therapy in recurrent or persistent ovarian cancer.
G. Cormio (2011)
10.1007/s10549-007-9591-y
Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer
K. Lee (2007)
Green tea polyphenol epigallocatechin-3 gallate inhibits Her-2/neu signaling, proliferation, and transformed phenotype of breast cancer cells.
S. Pianetti (2002)
10.1208/s12249-014-0113-z
Polymeric Micelles: Nanocarriers for Cancer-Targeted Drug Delivery
Y. Zhang (2014)
10.1186/s12951-017-0308-z
Metal nanoparticles: understanding the mechanisms behind antibacterial activity
Yael N. Slavin (2017)
10.1016/j.jconrel.2011.06.005
Dendrimer phthalocyanine-encapsulated polymeric micelle-mediated photochemical internalization extends the efficacy of photodynamic therapy and overcomes drug-resistance in vivo.
Hsueh-Lin Lu (2011)
10.1158/1078-0432.CCR-08-3289
Receptor-Targeted Nanoparticles for In vivo Imaging of Breast Cancer
Lily L. Yang (2009)
10.2174/1381612822666160617112111
Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective.
J. Ahmad (2016)
10.15272/AJBPS.V2I14.123
Nanopharmaceuticals: A New Perspective of Drug Delivery System
Md. Zubayer Hossain Saad (2012)
10.3389/fphar.2013.00028
Mechanisms and insights into drug resistance in cancer
H. Zahreddine (2013)
10.1097/00001813-200206000-00002
Acronycine derivatives as promising antitumor agents.
N. Guilbaud (2002)
10.1021/mp500744m
Synergistically Enhanced Therapeutic Effect of a Carrier-Free HCPT/DOX Nanodrug on Breast Cancer Cells through Improved Cellular Drug Accumulation.
F. Chen (2015)
10.1097/00001813-200104000-00003
Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel
J. M. Meerum Terwogt (2001)
10.1186/1556-276X-7-144
Magnetic nanoparticles: preparation, physical properties, and applications in biomedicine
A. Akbarzadeh (2012)
10.1016/j.biomaterials.2008.09.014
The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma.
Zhenghong Xu (2009)
10.1080/10408398.2016.1263597
Resveratrol as an anti-cancer agent: A review
A. Rauf (2018)
10.1016/j.actbio.2008.02.002
A stimulus-responsive magnetic nanoparticle drug carrier: magnetite encapsulated by chitosan-grafted-copolymer.
Q. Yuan (2008)
10.1016/j.bmc.2013.04.059
Novel artemisinin derivatives with potential usefulness against liver/colon cancer and viral hepatitis.
A. G. Blazquez (2013)
10.1002/JBM.A.31537
Folate-functionalized polymeric micelles for tumor targeted delivery of a potent multidrug-resistance modulator FG020326.
Xiaoqiang Yang (2008)
10.1023/A:1008348010437
Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial.
A. Sarris (2000)
10.1016/j.biomaterials.2011.04.029
The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-distearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells.
X. Wang (2011)
10.1007/s10495-015-1169-2
Cell death mechanisms of plant-derived anticancer drugs: beyond apoptosis
H. Gali-Muhtasib (2015)
10.2174/187152012803529736
Anti-cancer effects of curcumin on head and neck cancers.
W. Gao (2012)
10.1111/j.1349-7006.1997.tb00350.x
Anti‐tumor Efficacy of Paclitaxel against Human Lung Cancer Xenografts
T. Yamori (1997)
10.1002/JPS.10283
Effect of flavonoids on MRP1-mediated transport in Panc-1 cells.
H. Nguyen (2003)
10.3109/1061186X.2012.723213
Biological rationale for the design of polymeric anti-cancer nanomedicines
Y. Zhou (2013)
10.3892/ijmm.2012.1167
Vincristine induces cell cycle arrest and apoptosis in SH-SY5Y human neuroblastoma cells.
Y. Tu (2013)
10.1126/SCIENCE.275.5297.218
Cancer Chemopreventive Activity of Resveratrol, a Natural Product Derived from Grapes
M. Jang (1997)
10.1038/bjc.1996.313
An improved method of encapsulation of doxorubicin in liposomes: pharmacological, toxicological and therapeutic evaluation.
P. Gokhale (1996)
10.1111/j.1751-7915.2010.00221.x
Natural products for cancer chemotherapy
A. Demain (2011)
10.1016/0959-8049(92)90139-S
Vinblastine in metastatic renal cell carcinoma: EORTC phase II trial 30882. The EORTC Genitourinary Group.
S. Fossa (1992)
10.1039/C5RA03316K
Nanomedicines for targeted delivery of etoposide to non-small cell lung cancer using transferrin functionalized nanoparticles
D. Pooja (2015)
10.1016/j.ijbiomac.2017.03.095
Protein-drug nanoconjugates: Finding the alternative proteins as drug carrier.
Iqra Munir (2017)
10.1016/S1734-1140(13)71021-1
Synergistic anti-cancer activity of the combination of dihydroartemisinin and doxorubicin in breast cancer cells.
Guosheng Wu (2013)
10.1155/2012/247597
Antitumor Activity of Artemisinin and Its Derivatives: From a Well-Known Antimalarial Agent to a Potential Anticancer Drug
M. P. Crespo-Ortiz (2012)
10.3892/or.2011.1465
Antitumor activity of IHL-305, a novel pegylated liposome containing irinotecan, in human xenograft models.
T. Matsuzaki (2012)
10.1002/1097-0142(196310)16:10<1302::AID-CNCR2820161011>3.0.CO;2-A
Vincristine in the treatment of acute leukemia in children
A. Evans (1963)
10.1182/BLOOD.V26.5.642.642
The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia.
E. Frei (1965)
10.1111/j.1468-3083.2011.04404.x
Oral etoposide as first‐line therapy in the treatment of patients with advanced classic Kaposi’s sarcoma (CKS): a single‐arm trial (oral etoposide in CKS)
F. Tas (2013)
10.1038/s41467-017-02390-7
Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer
R. Qi (2017)
10.1016/J.CBI.2007.09.001
Epigallocatechin-3-gallate (EGCG) inhibits PC-3 prostate cancer cell proliferation via MEK-independent ERK1/2 activation.
Daniel S Albrecht (2008)
10.1039/c2mb05486h
Resveratrol downregulates Akt/GSK and ERK signalling pathways in OVCAR-3 ovarian cancer cells.
D. Vergara (2012)
10.1158/0008-5472.CAN-08-3978
Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate.
I. A. Siddiqui (2009)
10.1016/j.fct.2012.06.035
In vitro effect of quercetin on human gastric carcinoma: targeting cancer cells death and MDR.
S. Borska (2012)
10.2174/138920112798868791
Curcumin and liver cancer: a review.
A. S. Darvesh (2012)
10.1007/s00280-014-2602-x
Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors
D. Mahalingam (2014)
10.1093/annonc/mdu025
A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC).
A. Awada (2014)
10.1186/1477-3155-9-55
Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines
A. Mahapatro (2011)
10.1186/s12645-017-0030-4
Cancer resistance to treatment and antiresistance tools offered by multimodal multifunctional nanoparticles
E. Casals (2017)
10.1007/s10637-011-9709-2
Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer
K. Kato (2011)
10.2174/1871530315666150316120458
Curcumin targets in inflammation and cancer.
Atsuko Deguchi (2015)
10.1007/s00280-015-2737-4
A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax®) in patients with peritoneal malignancies
S. Williamson (2015)
10.3389/fphar.2014.00159
Nanodrug delivery in reversing multidrug resistance in cancer cells
Sonali Kapse-Mistry (2014)
10.1016/j.phymed.2016.07.005
Anti-cancer effect of (-)-epigallocatechin-3-gallate (EGCG) in head and neck cancer through repression of transactivation and enhanced degradation of β-catenin.
Y. Shin (2016)
10.1016/j.bcp.2011.09.015
Vincristine potentiates the anti-proliferative effect of an aurora kinase inhibitor, VE-465, in myeloid leukemia cells.
Kozue Yoshida (2011)
10.1042/BST0350061
Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging.
D. Tomalia (2007)
10.1158/1078-0432.CCR-11-1554
Pharmacokinetics and Antitumor Efficacy of XMT-1001, a Novel, Polymeric Topoisomerase I Inhibitor, in Mice Bearing HT-29 Human Colon Carcinoma Xenografts
Mark D. Walsh (2012)
10.1021/NP030304+
Antitumor activity of bruceantin: an old drug with new promise.
M. Cuendet (2004)
10.3389/fchem.2014.00020
Cancer wars: natural products strike back
Christine Basmadjian (2014)
10.3892/ETM.2015.2749
Biological and therapeutic activities, and anticancer properties of curcumin.
D. Perrone (2015)
10.1158/0008-5472.CAN-06-4762
Dendrimer-modified magnetic nanoparticles enhance efficiency of gene delivery system.
Bifeng Pan (2007)
DNA-based Artificial Nanostructures: Fabrication, Properties, and Applications
Y. Sun (2005)
10.1590/S0100-879X1999000800001
P-glycoprotein-mediated resistance to chemotherapy in cancer cells: using recombinant cytosolic domains to establish structure-function relationships.
A. di Pietro (1999)
10.1080/14740338.2018.1394454
Efficacy and safety of a combination of HER2-targeted agents as first-line treatment for metastatic HER2-positive breast cancer: a network meta-analysis
H. W. Leung (2018)
10.2174/1568011053174864
Cytotoxic and antitumor potentialities of aporphinoid alkaloids.
C. Stévigny (2005)
10.1158/1078-0432.CCR-08-0515
Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors
G. Batist (2009)
10.3390/molecules20022973
Indole Alkaloids from Catharanthus roseus: Bioproduction and Their Effect on Human Health
L. Almagro (2015)
10.1159/000443404
Natural Products as a Vital Source for the Discovery of Cancer Chemotherapeutic and Chemopreventive Agents
G. Cragg (2015)
10.1016/j.bcp.2009.08.013
Anti-cancer effects of artesunate in a panel of chemoresistant neuroblastoma cell lines.
M. Michaelis (2010)
10.1007/BF00684876
Teniposide: overview of its therapeutic potential in adult cancers
F. Muggia (2004)
10.1039/c7nr06898k
EGFR-targeting PLGA-PEG nanoparticles as a curcumin delivery system for breast cancer therapy.
H. Jin (2017)
10.1200/JCO.2017.74.3062
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).
L. Horn (2017)
10.1016/j.jconrel.2012.03.020
Doxil®--the first FDA-approved nano-drug: lessons learned.
Y. Barenholz (2012)
10.1093/annonc/mdq438
Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma.
A. Bedikian (2011)
10.1089/cbr.2009.0724
Anticancer activity and molecular mechanism of resveratrol-bovine serum albumin nanoparticles on subcutaneously implanted human primary ovarian carcinoma cells in nude mice.
Li-Yuan Guo (2010)
10.1016/j.biomaterials.2014.06.040
Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer.
Murali M Yallapu (2014)
10.1016/S1470-2045(13)70429-7
Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.
A. Awada (2013)
10.1016/j.addr.2013.09.019
Nanomedicine therapeutic approaches to overcome cancer drug resistance.
Janet L Markman (2013)
10.1634/THEONCOLOGIST.9-SUPPL_2-24
Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience.
J. Crown (2004)
10.3390/jpm7040012
Personalized Nanomedicine: A Revolution at the Nanoscale
C. Fornaguera (2017)
10.1038/bonekey.2014.94
Plant-derived anticancer agents: a promising treatment for bone metastasis.
P. Juárez (2014)
10.1021/nn200693a
Aptamer-conjugated DNA icosahedral nanoparticles as a carrier of doxorubicin for cancer therapy.
Microsugar Chang (2011)
10.1016/j.ejmech.2011.07.057
Natural products: an evolving role in future drug discovery.
B. Mishra (2011)
10.1016/j.hoc.2013.10.010
Combination chemoradiotherapy in early Hodgkin lymphoma.
Marc P E André (2014)
10.1038/sj.clpt.6100400
Nanoparticles in Medicine: Therapeutic Applications and Developments
L. Zhang (2008)
Antivasculature effects of doxorubicin-containing liposomes in an intracranial rat brain tumor model.
R. Zhou (2002)
10.1124/jpet.117.243931
Pharmacokinetic/Pharmacodynamic Modeling of Schedule-Dependent Interaction between Docetaxel and Cabozantinib in Human Prostate Cancer Xenograft Models
W. Chen (2018)
10.1136/thorax.57.1.20
Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review
A. Clegg (2002)
10.1016/j.nano.2009.12.006
Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy.
K. W. Kang (2010)
Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models.
P. Tardi (2000)
10.1021/nn2033105
Controlled intracellular release of doxorubicin in multidrug-resistant cancer cells by tuning the shell-pore sizes of mesoporous silica nanoparticles.
Y. Gao (2011)
10.1016/S0169-5002(03)90519-8
The role of topotecan in treating small cell lung cancer: second-line treatment
J. Pawel (2003)
10.1002/adma.201002767
A DNA nanostructure-based biomolecular probe carrier platform for electrochemical biosensing.
H. Pei (2010)
10.1016/j.jconrel.2008.01.013
Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy.
Kyung Hyun Min (2008)
10.1016/j.biomaterials.2011.04.022
Multifunctional nanoassemblies for vincristine sulfate delivery to overcome multidrug resistance by escaping P-glycoprotein mediated efflux.
P. Zhang (2011)
10.1016/j.jconrel.2009.11.008
Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery.
J. Li (2010)
10.1016/j.addr.2012.03.008
Triazine dendrimers as drug delivery systems: from synthesis to therapy.
Jongdoo Lim (2012)
10.1186/s12885-016-2999-1
Molecular chess? Hallmarks of anti-cancer drug resistance
I. Cree (2016)
Current studies of ifosfamide for pediatric solid tumors and leukemia in the United States.
C. Pratt (1992)
10.1016/J.TIBTECH.2006.02.004
Nanoparticles as targeting ligands.
K. Jain (2006)
10.1200/JCO.1988.6.2.351
Teniposide in the treatment of leukemia: a case study of conflicting priorities in the development of drugs for fatal diseases.
J. Grem (1988)
10.1002/cncr.24359
Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non‐Hodgkin lymphoma
M. Rodriguez (2009)
10.1177/1758834016688816
Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy
E. Kipps (2017)
10.1016/0005-2736(94)00235-H
Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro.
R. Lee (1995)
10.1200/JCO.1993.11.7.1245
Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy.
P. Fumoleau (1993)
10.1186/s12885-015-1017-3
Ewing sarcoma of the liver with multilocular cystic mass formation: a case report
Y. Ozaki (2015)
10.1007/s11671-009-9431-6
A Novel Docetaxel-Loaded Poly (ε-Caprolactone)/Pluronic F68 Nanoparticle Overcoming Multidrug Resistance for Breast Cancer Treatment
L. Mei (2009)
10.1016/j.biomaterials.2011.08.041
Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel -polymer micelles to overcome multi-drug resistance.
Feihu Wang (2011)
10.2174/1871520615666150116102442
Curcumin-based anti-prostate cancer agents.
Q. Chen (2015)
10.1007/s00280-012-2048-y
A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies
J. Deeken (2012)
10.1021/am5090226
Dual drug conjugated nanoparticle for simultaneous targeting of mitochondria and nucleus in cancer cells.
Abhik Mallick (2015)
10.1038/nnano.2009.235
Diagnosing lung cancer in exhaled breath using gold nanoparticles.
G. Peng (2009)
10.17179/excli2015-561
Molecular mechanisms of etoposide
A. Montecucco (2015)
10.1021/acs.jnatprod.5b01055
Natural Products as Sources of New Drugs from 1981 to 2014.
D. Newman (2016)
10.1155/2017/9090325
Targeted Therapeutic Nanoparticles: An Immense Promise to Fight against Cancer
S. Jahan (2017)
10.1021/mp400547u
Multifunctional nanoparticles as nanocarrier for vincristine sulfate delivery to overcome tumor multidrug resistance.
Y. Wang (2014)
10.1016/S0006-2952(02)00899-7
Induction of apoptosis in HL-60 leukemia and B16 melanoma cells by the acronycine derivative S23906-1.
J. Kluza (2002)
10.1007/s00432-017-2380-z
Curcumin induces G2/M arrest, apoptosis, NF-κB inhibition, and expression of differentiation genes in thyroid carcinoma cells
S. Schwertheim (2017)



Semantic Scholar Logo Some data provided by SemanticScholar